Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation.

Study summary

Main finding

Treatment reduced bone loss and affected AMPK-related osteoclast differentiation in the model.

What was studied: Ovariectomized mice and osteoclast experiments
How the study was set up: Mice after ovary removal were studied over 12 weeks, alongside experiments on formation of bone-resorbing cells.
What the researchers measured: Micro-CT bone loss, osteoclast differentiation, and AMPK activation with inhibitor comparisons were assessed.
How to read this evidence: Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.

The study links a mouse bone-loss outcome with a cell pathway. It does not establish fracture prevention or osteoporosis treatment in people.

An induced mouse model does not establish prevention or treatment of human osteoporosis.

Why this paper is included: The compound is a named subject of the publication title.
Publication indexing: Journal Article · Research Support, Non-U.S. Gov't
Indexed subjects: AMP-Activated Protein Kinases · Animals · Cell Differentiation · Enzyme Activation · Female · Gene Expression Regulation · Mice, Inbred C57BL · Mitochondrial Proteins · Osteoblasts · Osteoclasts · Osteoporosis · Ovariectomy · Peptides · RANK Ligand · X-Ray Microtomography
Source checked: October 4, 2026. Years follow journal issues; online-first dates may differ.

Educational research information. A publication does not verify the identity, quality, or safety of products sold here.

Study summary

Treatment reduced bone loss and affected AMPK-related osteoclast differentiation in the model.

What was studied: Ovariectomized mice and osteoclast experiments
How the study was set up: Mice after ovary removal were studied over 12 weeks, alongside experiments on formation of bone-resorbing cells.
What the researchers measured: Micro-CT bone loss, osteoclast differentiation, and AMPK activation with inhibitor comparisons were assessed.
How to read this evidence: Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.

The study links a mouse bone-loss outcome with a cell pathway. It does not establish fracture prevention or osteoporosis treatment in people.

An induced mouse model does not establish prevention or treatment of human osteoporosis.

Why this paper is included: The compound is a named subject of the publication title.
Publication indexing: Journal Article · Research Support, Non-U.S. Gov't
Indexed subjects: AMP-Activated Protein Kinases · Animals · Cell Differentiation · Enzyme Activation · Female · Gene Expression Regulation · Mice, Inbred C57BL · Mitochondrial Proteins · Osteoblasts · Osteoclasts · Osteoporosis · Ovariectomy · Peptides · RANK Ligand · X-Ray Microtomography
Source checked: October 4, 2026. Years follow journal issues; online-first dates may differ.

Educational research information. A publication does not verify the identity, quality, or safety of products sold here.